Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Redistributes Responsibility For 370 Drugs Currently Overseen By UK

Executive Summary

The EMA has completed the reallocation to the EU27 member states of more than 370 centrally authorized drugs for which the UK was rapporteur or co-rapporteur. The move has been necessitated by Brexit, which means the UK will no longer play an active role in new drug evaluations at the EMA.


Related Content

‘We’ll Manage,’ Danish Medicines Agency Head’s View On Brexit
The Tricky Task Of Bringing Smaller EU Countries Into The Fold
EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses
EMA Tackles Tough Job Of Filling UK Void In Working Parties
Industry And Regulators Thrash Out Brexit Concerns At Stakeholder Meeting
BIA Head Attacks Rapporteur Reallocation, But Welcomes Further Clarity On Transition Period
CMDh Steps In As Firm Finds No Takers To Replace UK As Reference Member State
Brexit Won’t Delay Drug Approvals, EMA’s Rasi Reassures Industry
‘Do Not Rely On The Brexit Transition Period!’ EC Warns Hesitant Pharma Firms
UK MHRA ‘Pushback’ Against Efforts To Sideline It From EU Processes





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts